$9.55 Billion is the total value of Flagship Pioneering Inc.'s 38 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Sell | Moderna Inc | $6,766,230,000 | +39.9% | 17,581,016 | -14.6% | 70.86% | +14.7% |
| SANA | Sana Biotechnology Inc | $771,063,000 | +14.5% | 34,239,018 | 0.0% | 8.08% | -6.1% | |
| RUBY | Rubius Therapeutics Inc | $688,497,000 | -26.8% | 38,506,526 | 0.0% | 7.21% | -39.9% | |
| New | Omega Therapeutics Inc | $488,258,000 | – | 25,902,269 | +100.0% | 5.11% | – | |
| FHTX | Foghorn Therapeutics Inc | $176,551,000 | +30.6% | 12,674,120 | 0.0% | 1.85% | +7.1% | |
| EVLO | Evelo Biosciences Inc | $162,131,000 | -48.8% | 23,030,069 | 0.0% | 1.70% | -58.0% | |
| DNLI | Denali Therapeutics Inc | $137,742,000 | -35.7% | 2,730,263 | 0.0% | 1.44% | -47.3% | |
| KLDO | Kaleido Biosciences Inc | $106,883,000 | -26.6% | 19,575,710 | 0.0% | 1.12% | -39.8% | |
| MCRB | Seres Therapeutics Inc | $100,076,000 | -70.8% | 14,378,802 | 0.0% | 1.05% | -76.1% | |
| SGTX | Sigilon Therapeutics Inc | $58,592,000 | -47.3% | 10,370,369 | 0.0% | 0.61% | -56.8% | |
| CDAK | Codiak Biosciences Inc | $42,578,000 | -11.9% | 2,607,303 | 0.0% | 0.45% | -27.7% | |
| AXLA | Axcella Health Inc | $37,394,000 | -25.7% | 12,548,414 | 0.0% | 0.39% | -39.0% | |
| SYRS | Syros Pharmaceuticals Inc | $13,135,000 | -18.0% | 2,938,494 | 0.0% | 0.14% | -32.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
- Flagship Opportunities Fund I General Partner LLC #4
- Flagship Pioneering Special Opportunities Fund II General Partner LLC #5
- Nutritional Health Fund LTP General Partner LLC #6
- Flagship Pioneering Fund VI General Partner LLC #7
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.